Dilution Information
()
Rabbit PRAME Monoclonal Antibody | anti-PRAME antibody
PRAME, Rmab
Applications
Immunohistochemistry
Synonyms
PRAME; Monoclonal Antibody; Rmab; anti-PRAME antibody
Host
Rabbit
Clonality
Monoclonal
Isotype
IgG
Clone Number
RBT-PRAME
Form/Format
Concentrate or Prediluted
Sequence Length
509
Applicable Applications for anti-PRAME antibody
Immunohistochemistry (IHC) Frozen/Paraffin
Immunogen
Synthetic peptide corresponding to residues of human PRAME protein.
Localization
Cytoplasmic, Nuclear
Control
Tonsil, Seminoma
Intended Use
This antibody is intended for use in Immunohistochemical applications on formalinfixed paraffin-embedded tissues (FFPE), frozen tissue sections and cell preparations. Interpretation of results should be performed by a qualified medical professional.
Preparation and Storage
Store at 2-8 degree C.
Dilution Information
()
Dilution Information
()
Immunohistochemistry (IHC)
(IHC PRAME on a Testis Tissue)
Immunohistochemistry (IHC)
(IHC PRAME on a Testis Tissue)
Related Product Information for anti-PRAME antibody
Melanoma antigen preferentially expressed in tumors is a protein that in humans is encoded by the PRAME gene. This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except in testis. This expression pattern is like that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. PRAME overexpression in triple negative breast cancer has also been found to promote cancer cell motility through induction of the epithelial-to-mesenchymal transition.
PRAME mRNA expression is well documented in cutaneous and ocular melanomas. One study concluded that diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83.2% of primary melanomas. Among melanoma subtypes, PRAME was diffusely expressed in 94.4% of acral melanomas, 92.5% of superficial spreading melanomas, 90% of nodular melanomas, 88.6% of lentigo maligna melanomas, and 35% of desmoplastic melanomas. When in situ and nondesmoplastic invasive melanoma components were present, PRAME expression was seen in both. Most Melanocytic nevi (86.4%), were completely negative for PRAME. Immunoreactivity for PRAME was seen, albeit usually only in a minor subpopulation of lesional melanocytes, in 13.6% of cutaneous nevi, including dysplastic nevi, common acquired nevi, traumatized/recurrent nevi, and Spitz nevi. Rare isolated junctional melanocytes with immunoreactivity for PRAME were also seen in solar lentigines and benign nonlesional skin. This study suggests that immunohistochemical analysis for PRAME expression may be useful for identification purposes to support a suspected identification of melanoma. It may also be valuable for margin assessment of a known PRAME-positive melanoma, but its expression in nevi, solar lentigines, and benign nonlesional skin can represent a challenge.
PRAME mRNA expression is well documented in cutaneous and ocular melanomas. One study concluded that diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83.2% of primary melanomas. Among melanoma subtypes, PRAME was diffusely expressed in 94.4% of acral melanomas, 92.5% of superficial spreading melanomas, 90% of nodular melanomas, 88.6% of lentigo maligna melanomas, and 35% of desmoplastic melanomas. When in situ and nondesmoplastic invasive melanoma components were present, PRAME expression was seen in both. Most Melanocytic nevi (86.4%), were completely negative for PRAME. Immunoreactivity for PRAME was seen, albeit usually only in a minor subpopulation of lesional melanocytes, in 13.6% of cutaneous nevi, including dysplastic nevi, common acquired nevi, traumatized/recurrent nevi, and Spitz nevi. Rare isolated junctional melanocytes with immunoreactivity for PRAME were also seen in solar lentigines and benign nonlesional skin. This study suggests that immunohistochemical analysis for PRAME expression may be useful for identification purposes to support a suspected identification of melanoma. It may also be valuable for margin assessment of a known PRAME-positive melanoma, but its expression in nevi, solar lentigines, and benign nonlesional skin can represent a challenge.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The PRAME (Catalog #AAA370382) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's PRAME can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC) Frozen/Paraffin. Researchers should empirically determine the suitability of the PRAME for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "PRAME, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
